leisure time -WSS

leisure time

author：knowledge 2025-10-02 23:47:09 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： CDC Director Mandy Cohen on transparency, trust, and health

WSS

Dems pitch expanding Medicare power to negotiate drug prices

Roche’s Alnylam deal shows drug firms interested in heart drugs

The Sacklers, horror, and ‘The Fall of the House of Usher’

New Alzheimer's drugs heat up race for early detection blood tests

Rise in cancer among younger people worries and puzzles doctors

UHS says company favors patients whose insurance pays more

focus

leisure time

Gilead needs Arcellx more than ever

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Rise in cancer among younger people worries and puzzles doctors

Apple is now the first public company to be valued at $3 trillion

A clever new way to fix Medicaid and graduate medical education

Anesthesiologist group: stop taking Ozempic before surgery

Roche’s Alnylam deal shows drug firms interested in heart drugs

Supreme Court strikes down use of affirmative action

Medicare will require more price transparency from hospitals

Anesthesiologist group: stop taking Ozempic before surgery

Dems pitch expanding Medicare power to negotiate drug prices

explore

Device maker Teleflex to acquire urology company for $600M

STAT Executive Editor Rick Berke on STAT's 8th birthday

Former reverend arrested for allegedly killing 8

Sanofi CEO defends move to abandon profit guidance, boost research

Abortion clinic in Cancun will cater to Americans

In the gardens at Boston Children's Hospital, families find sanctuary

knowledge

leisure time

focus

focus